Fierce Biotech

Roche's return to RNA continues with $1.7B deal for Sanegene program

Roche is continuing its return to the RNA space by paying $200 million for the worldwide license to one of SanegeneBio’s ...
Hosted on MSN

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit

Roche and Zealand Pharma in March struck a deal worth up to $5.3 billion to co-develop and co-commercialize amylin analog petrelintide as a potentially "next generation" weight loss drug. Executives ...
Fierce Biotech

Roche drops $100M Kiniksa fibrosis drug from phase 2 pipeline as part of quarterly clearout

Roche has waved goodbye to an inflammation drug from Kiniksa Pharmaceuticals—as well as the $100 million that the pharma paid for the therapy—as part of a ...

Drugmakers turn to AI to speed trials, regulatory submissions

By Maggie Fick and Michael Erman SAN FRANCISCO, Jan 26 (Reuters) - Artificial intelligence has yet to deliver on the most ...
Yahoo Finance

AI in Drug Discovery Market Research Report 2026-2040: NVIDIA, Insilico Medicine, Google DeepMind, Pfizer, and Roche Leveraging AI Platforms to Accelerate Development Timelines ...

Dublin, Jan. 19, 2026 (GLOBE NEWSWIRE) -- The "AI in Drug Discovery Market, till 2040: Distribution by Drug Discovery Steps, Therapeutic Area, and Key Geographical Regions: Industry Trends and Global ...

Roche obesity drug shows 22.5% weight loss as it seeks to catch up with Lilly, Novo

BERLIN, Jan 27 (Reuters) - Roche's experimental obesity drug, which works in a similar way to Eli Lilly's Zepbound, produced ...
NBC Washington

Inside the deal: Roche and Zealand Pharma's $5.3 billion obesity drug gambit

COPENHAGEN, Denmark — The ballooning obesity drug market may have a new contender after Roche struck a $5.3 billion deal to develop Danish biotech Zealand Pharma's "next generation" weight loss ...